NCT03103893View on ClinicalTrials.gov

Novel Compositions for Treating or Preventing Dermal Disorders

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 25, 2017

Primary Completion Date

November 30, 2017

Study Completion Date

November 30, 2017

Conditions
Dermal Atrophy
Interventions
DRUG

Rapamycin

topical formulation

Trial Locations (1)

19102-1101

Drexel Dermatology, Philadelphia

All Listed Sponsors
lead

Drexel University

OTHER

NCT03103893 - Novel Compositions for Treating or Preventing Dermal Disorders | Biotech Hunter | Biotech Hunter